RNS60 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4
13	多発性硬化症／視神経脊髄炎	2

2. 筋萎縮性側索硬化症

---

臨床試験数 : 624 /  薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02988297 (ClinicalTrials.gov)	November 2022	7/12/2016	Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis	Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: RNS60;Drug: Placebo	Revalesio Corporation	NULL	Not yet recruiting	18 Years	80 Years	All	140	Phase 2	NULL
2	EUCTR2016-002382-62-IT (EUCTR)	13/01/2017	22/06/2021	The effects of RNS60 on ALS biomarkers	The effects of RNS60 on ALS biomarkers - RNS60-ALS	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1;Level: LLT;Classification code 10052889;Term: ALS;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: RNS60 Product Code: RNS60 Product Name: RNS60 Product Code: RNS60	IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	142	Phase 2	United States;Italy
3	NCT03456882 (ClinicalTrials.gov)	November 18, 2016	2/2/2018	The Effect of RNS60 on ALS Biomarkers	The Effect of RNS60 on ALS Biomarkers	Amyotrophic Lateral Sclerosis	Drug: RNS60	Mario Negri Institute for Pharmacological Research	ALS Association;Get out ONLUS	Completed	18 Years	80 Years	All	142	Phase 2	United States;Italy
4	NCT02525471 (ClinicalTrials.gov)	October 2015	12/8/2015	A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)		ALS	Drug: RNS60	Sabrina Paganoni, M.D.	NULL	Completed	18 Years	80 Years	All	24	Phase 1	United States

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-000221-20-AT (EUCTR)	23/10/2014	25/06/2014	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: RNS60 Product Code: RNS60	University Hospital Zürich	NULL	Not Recruiting			Female: yes Male: yes	16	Phase 2	Austria;Switzerland
2	NCT01714089 (ClinicalTrials.gov)	March 2013	19/10/2012	Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis	A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: RNS60 125 ml;Drug: RNS60 250 ml;Drug: Interferon beta 1a	Revalesio Corporation	NULL	Withdrawn	18 Years	50 Years	Both	0	Phase 2	United States

先頭へ